• Apyx Medical’s third-quarter 2026 net loss attributable to stockholders narrowed 10% year over year to $1.8 million.
• Total revenue rose 9% to $14 million, while Surgical Aesthetics revenue climbed 17% to $13 million.
• OEM revenue fell 42% to approximately $1.1 million due to lower sales volume to existing customers.
• The full commercial launch of the AYON system’s reusable power liposuction handpiece began following positive feedback from early-adopter surgeons.
• Reaffirmed FY26 revenue guidance of $59 million to $60 million, while cutting its operating expense forecast to $41 million to $42.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apyx Medical Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.